Q-omics provides the consensus-scored IMPDH1P6 profile across patient tissues and cancer cell-line models. IMPDH1P6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IMPDH1P6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IMPDH1P6 RNA expression shows 15,305 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where IMPDH1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMPDH1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMPDH1P6 survival associations across molecular data types. IMPDH1P6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMPDH1P6 RNA expression–survival associations across cancer types. High IMPDH1P6 expression shows unfavorable associations in ACC, KIRC, UVM and UCEC, but favorable associations in HNSC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for IMPDH1P6 RNA expression.
This table summarizes IMPDH1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IMPDH1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMPDH1P6 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, BRCA and LUSC. The HNSC box plot shows higher IMPDH1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.149, t-test p < 0.001).
This table shows molecular features associated with IMPDH1P6 in patient tissues and cancer cell lines. In patient samples, IMPDH1P6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
